查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591980

免疫肿瘤学市场：按类型、适应症和最终用户划分 - 全球预测 2025-2030

Immuno-Oncology Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年免疫肿瘤市值为53.6亿美元，预计2024年将达到58.9亿美元，复合年增长率为9.99%，到2030年将达到104.5亿美元。

免疫肿瘤学是一个快速发展的领域，专注于利用人体的免疫系统来对抗癌症。它包括旨在提高癌症患者的生存率和生活品质的各种治疗方法，例如免疫查核点抑制剂、癌症疫苗和细胞疗法。免疫肿瘤学的需求源于传统癌症治疗的局限性，例如化疗，通常会引起严重的副作用，并且控制疾病的效果有限。该领域旨在提供有针对性的干预措施，激活特异性针对癌细胞的免疫反应，为癌症治疗提供一种有前途的替代方案。免疫肿瘤学有广泛的应用，从治疗各种癌症类型（如黑色素瘤、肺癌和大肠癌）到提高疗效的联合治疗。最终用途范围主要针对医院、癌症研究中心和专科诊所。

主要市场统计
基准年[2023] 53.6亿美元
预测年份 [2024] 58.9亿美元
预测年份 [2030] 104.5亿美元
复合年增长率（%） 9.99%

免疫肿瘤学市场受到癌症发生率增加、生物技术进步以及对肿瘤免疫学了解加深等因素的影响。对个人化医疗的需求不断增长以及对研发的持续关注将进一步推动市场成长。然而，某些癌症的治疗成本高、监管途径复杂以及患者反应有限等挑战构成了重大障碍。儘管面临这些挑战，该领域仍存在利润丰厚的商机，包括开髮用于患者分层的新型生物标记、提高联合治疗的疗效以及扩大细胞疗法的应用等。创新比比皆是，例如探索双特异性抗体、提高 T 细胞疗法的功效以及利用人工智慧进行药物发现和开发。

为了抓住这些机会，相关人员应专注于合作研究、与生技公司的策略联盟以及对新兴技术的投资。此外，解决与成本相关的挑战和改善患者获得治疗的机会仍然至关重要。市场动态是充满活力和竞争的，其特点是技术快速进步和对临床试验的重视。持续创新和策略适应不断变化的科学见解和市场需求对于这个变革领域的持续成长和成功至关重要。

市场动态：揭示快速发展的免疫肿瘤学市场的关键市场洞察

供需的动态交互作用正在改变免疫肿瘤学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症患者数量增加
    • 政府积极主动控制癌症
    • 人们越来越偏好免疫疗法和标靶治疗
  • 市场限制因素
    • 与免疫肿瘤学相关的高额医疗费用
  • 市场机会
    • 研究开发活动资金筹措快速增加
    • 扩大个人化医疗和精准肿瘤学
  • 市场挑战
    • 对免疫肿瘤学对健康的负面影响的担忧

波特五力：驾驭免疫肿瘤学市场的策略工具

波特的五力框架是了解免疫肿瘤学市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解免疫肿瘤学市场的外部影响

外部宏观环境因素在塑造免疫肿瘤学市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解免疫肿瘤学市场的竞争格局

免疫肿瘤学市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵免疫肿瘤学市场供应商的绩效评估

FPNV定位矩阵是评估免疫肿瘤市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了免疫肿瘤学市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，免疫肿瘤学市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症患者的负担不断增加
      • 政府首选的癌症控制方法
      • 人们对免疫疗法和标靶治疗的兴趣日益浓厚
    • 抑制因素
      • 与免疫肿瘤学相关的高额医疗费用
    • 机会
      • 研究开发活动经费快速增加
      • 扩大个人化医疗和精准肿瘤学
    • 任务
      • 对免疫肿瘤学对健康的负面影响的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章免疫肿瘤学市场：依类型

  • 癌症疫苗
  • 查核点抑制剂
  • 细胞激素
  • 免疫细胞疗法（CAR-T）
  • 单株抗体

第七章依适应症分類的免疫肿瘤学市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 恶性黑色素瘤

第八章免疫肿瘤学市场：依最终用户分类

  • 学术/研究机构
  • 医院/诊所

第 9 章：美洲免疫肿瘤学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太免疫肿瘤市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的免疫肿瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Agilent Technologies, Inc.
  • Allogene Therapeutics
  • Amgen Inc.
  • Arcus Biosciences, Inc.
  • Asher Biotherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • Avantor, Inc.
  • BeiGene, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Cellectis SA
  • F. Hoffmann-La Roche AG
  • Fate Therapeutics Inc.
  • Merck KGaA
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Triumvira Immunologics Inc.
Product Code: MRR-FF012EDC38BF

The Immuno-Oncology Market was valued at USD 5.36 billion in 2023, expected to reach USD 5.89 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 10.45 billion by 2030.

Immuno-oncology is a rapidly advancing field focusing on harnessing the body's immune system to fight cancer. Its scope involves various therapies, such as immune checkpoint inhibitors, cancer vaccines, and cell therapies, which aim to improve survival rates and quality of life for cancer patients. The necessity of immuno-oncology stems from the limitations of traditional cancer therapies, such as chemotherapy, which often result in severe side effects and limited efficacy in controlling the disease. This field aims to provide targeted interventions that activate an immune response specifically against cancer cells, offering a promising alternative for cancer treatment. Applications of immuno-oncology span from treating various cancer types, including melanoma, lung, and colorectal cancers, to combination therapies that enhance effectiveness. The end-use scope primarily targets hospitals, cancer research centers, and specialized clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.36 billion
Estimated Year [2024] USD 5.89 billion
Forecast Year [2030] USD 10.45 billion
CAGR (%) 9.99%

The market for immuno-oncology is influenced by factors such as increased cancer prevalence, advancements in biotechnology, and improved understanding of tumor immunology. The rising demand for personalized medicine and the ongoing focus on R&D further propel market growth. However, challenges such as high treatment costs, complex regulatory pathways, and limited patient response in certain cancers pose significant hurdles. Despite these challenges, the field presents lucrative opportunities, particularly in developing novel biomarkers for patient stratification, enhancing the efficacy of combinatory therapies, and expanding the application of cell therapies. Innovations abound in exploring bispecific antibodies, enhancing T-cell therapy effectiveness, and leveraging AI for drug discovery and development.

To seize these opportunities, stakeholders should focus on collaborative research efforts, strategic partnerships with biotechnology firms, and investments in emerging technologies. Additionally, addressing cost-related challenges and improving patient access to therapies remain crucial. The nature of the immuno-oncology market is dynamic and highly competitive, characterized by rapid technological advancements and a strong emphasis on clinical trials. Continued innovation and strategic adaptation to evolving scientific insights and market demands are essential for sustained growth and success in this transformative field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno-Oncology Market

The Immuno-Oncology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of cancer cases across the globe
    • Favorable government initiatives for cancer management
    • Growing preference for immunotherapy and targeted therapies
  • Market Restraints
    • Associated high medical expenses of immuno-oncology
  • Market Opportunities
    • Surge in fundings for research and development activities
    • Expansion of personalized medicine and precision oncology
  • Market Challenges
    • Concern regarding adverse health impacts of immuno-oncology

Porter's Five Forces: A Strategic Tool for Navigating the Immuno-Oncology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno-Oncology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno-Oncology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno-Oncology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno-Oncology Market

A detailed market share analysis in the Immuno-Oncology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno-Oncology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno-Oncology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno-Oncology Market

A strategic analysis of the Immuno-Oncology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno-Oncology Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Agilent Technologies, Inc., Allogene Therapeutics, Amgen Inc., Arcus Biosciences, Inc., Asher Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, Avantor, Inc., BeiGene, Inc., Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cellectis SA, F. Hoffmann-La Roche AG, Fate Therapeutics Inc., Merck KGaA, Sanofi S.A., Thermo Fisher Scientific Inc., and Triumvira Immunologics Inc..

Market Segmentation & Coverage

This research report categorizes the Immuno-Oncology Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Cytokines, Immune Cell Therapy (CAR-T), and Monoclonal Antibodies.
  • Based on Indication, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma.
  • Based on End-Users, market is studied across Academic & Research Institutions and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of cancer cases across the globe
      • 5.1.1.2. Favorable government initiatives for cancer management
      • 5.1.1.3. Growing preference for immunotherapy and targeted therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Associated high medical expenses of immuno-oncology
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in fundings for research and development activities
      • 5.1.3.2. Expansion of personalized medicine and precision oncology
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding adverse health impacts of immuno-oncology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immuno-Oncology Market, by Type

  • 6.1. Introduction
  • 6.2. Cancer Vaccines
  • 6.3. Checkpoint Inhibitors
  • 6.4. Cytokines
  • 6.5. Immune Cell Therapy (CAR-T)
  • 6.6. Monoclonal Antibodies

7. Immuno-Oncology Market, by Indication

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Lung Cancer
  • 7.5. Melanoma

8. Immuno-Oncology Market, by End-Users

  • 8.1. Introduction
  • 8.2. Academic & Research Institutions
  • 8.3. Hospitals & Clinics

9. Americas Immuno-Oncology Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Immuno-Oncology Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Immuno-Oncology Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Adicet Bio, Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Allogene Therapeutics
  • 6. Amgen Inc.
  • 7. Arcus Biosciences, Inc.
  • 8. Asher Biotherapeutics, Inc.
  • 9. Astellas Pharma Inc.
  • 10. AstraZeneca PLC
  • 11. Atara Biotherapeutics, Inc.
  • 12. Autolus Therapeutics PLC
  • 13. Avantor, Inc.
  • 14. BeiGene, Inc.
  • 15. Bio-Rad Laboratories, Inc.
  • 16. BioNTech SE
  • 17. Boehringer Ingelheim International GmbH
  • 18. Bristol Myers Squibb
  • 19. Cellectis SA
  • 20. F. Hoffmann-La Roche AG
  • 21. Fate Therapeutics Inc.
  • 22. Merck KGaA
  • 23. Sanofi S.A.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Triumvira Immunologics Inc.

LIST OF FIGURES

  • FIGURE 1. IMMUNO-ONCOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNO-ONCOLOGY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNO-ONCOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNO-ONCOLOGY MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY IMMUNE CELL THERAPY (CAR-T), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2023